BLUEJET2024-10-012024-12-31 BLUEJET2024-10-012024-12-31 BLUEJET2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member BLUEJET2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member BLUEJET2024-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 544009 BLUEJET NOTLISTED Blue Jet Healthcare Limited Equity 2024-04-01 2025-03-31 2025-01-29 2025-01-22 INR Millions Third quarter 12:05:00 13:05:00 2025-01-29 2025-01-29 Not applicable Single segment Pharmaceutical and API'S 2024-10-01 2024-12-31 Unaudited Standalone 3183824000.00 132414000.00 3316238000.00 1712439000.00 0.00 -268241000.00 148251000.00 157000.00 47454000.00 351234000.00 1991294000.00 1324944000.00 0.00 1324944000.00 325000000.00 10113000.00 335113000.00 0.00 989831000.00 0.00 0.00 0.00 0.00 989831000.00 0.00 989831000.00 0.00 0.00 346931000.00 2 5.71 5.71 0.00 0.00 5.71 5.71 1. The above financial results of the Company for the three months and nine months ended December 31, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on January 29, 2025. Further, the above financial results have been reviewed by the Statutory Auditor of the Company. 2. The company is engaged in manufacturing of Pharma Intermediate, APIs used in Pharmaceutical and Healthcare products. 3. During the previous year, an incident at the Mahad facility resulted in a loss of damaged assets and compensation to employees aggregating to Rs 97.43 million, accounted for as an exceptional items by the company. 4. During the nine months ended December 31, 2024, the Company changed its method of depreciation from the Written Down Value (WDV) to the Straight-Line Method (SLM) based on the assessment of technical parameters of the said property plant & equipment, which indicates a more uniform consumption of economic benefits over time. Consequently, for the nine months ended December 31, 2024 and three months ended December 31, 2024 the depreciation expense is lower by and profit before tax is higher by Rs 108.48 million and Rs 36.79 million respectively. 5. The Company does not have any subsidiaries, associates, or joint ventures as on December 31, 2024. Consequently, the preparation of consolidated financial statements is not applicable. Single segment 2024-04-01 2024-12-31 Unaudited Standalone 6895404000.00 340314000.00 7235718000.00 3767639000.00 0.00 -690161000.00 450051000.00 637000.00 128424000.00 990244000.00 4646834000.00 2588884000.00 0.00 2588884000.00 600000000.00 37783000.00 637783000.00 0.00 1951101000.00 0.00 0.00 0.00 0.00 1951101000.00 0.00 1951101000.00 0.00 0.00 346931000.00 2 11.25 11.25 0.00 0.00 11.25 11.25 Other Expenses 351234000.00 Other Expenses 990244000.00 0.00 0.00 0.00 0.00